• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • Buyouts

Advent buys Industria Chimica Emiliana

  • Alessia Argentieri
  • Alessia Argentieri
  • 01 October 2019
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

Private equity firm Advent International has wholly acquired Industria Chimica Emiliana (ICE), an Italian company specialising in the production of cholic acid used for the treatment of gastric and liver diseases.

Unquote understands that the deal gives the company an enterprise value of around €600m, which equates to approximately 15x its EBITDA.

Advent won the auction for the company seeing off competition from several private equity rivals, including Bain Capital, Cinven and Astorg, according to press reports.

Industria Chimica Emiliana

  • DEAL:

    Buyout

  • VALUE:

    €600m

  • LOCATION:

    Reggio Emilia

  • SECTOR:

    Speciality chemicals

  • FOUNDED:

    1949

  • TURNOVER:

    €160m (2018)

  • EBITDA:

    €40m (2018)

  • STAFF:

    1,000

The vendors are the company's founding Bartoli family, who will continue to have an active role in the management with Enzo Bartoli as chair.

Unquote understands that the GP deployed capital from Advent International GPE IX, which held a final close in June 2019 on its hard-cap of $17.5bn. The vehicle writes equity tickets of $100m-1bn to invest in companies with enterprise value of $50m-3.5bn, operating in the healthcare, industrial, consumer, TMT and retail sectors, and based across North America and Europe.

In addition, KKR deployed a unitranche facility to support the acquisition of ICE, Unquote understands.

Advent intends to further strengthen the company's market position, develop its production capabilities and boost its expansion via a buy-and-build strategy, which will be pursued both in Italy and internationally.

Company
Founded in 1949, ICE specialises in manufacturing ursodeoxycholic acid (UDCA), an active pharmaceutical ingredient sourced from ox bile, primarily used in drugs treating gastric and liver diseases.

The company is headquartered in Reggio Emilia, with subsidiaries in Europe, Asia and North America, and employs 1,000 people. It generated an EBITDA margin of around 25% from revenues of €160m.

People
Advent International – Francesco Casiraghi (managing director).
Industria Chimica Emiliana – Enzo Bartoli (co-founder, chair).

Advisers
Equity – Freshfields Bruckhaus Deringer (legal); Kirkland & Elllis (legal); Ropes & Gray (legal); Mattos Filho (legal); AZB (legal); Deutsche Bank (corporate finance); Nomura (corporate finance).
Company – Bonelli Erede (legal); Studio Ferrarini (legal); PwC (financial due diligence).

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Buyouts
  • Southern Europe
  • Industrials
  • Healthcare
  • Advent International
  • Italy
  • KKR
  • PwC
  • Nomura
  • Deutsche Bank
  • Ropes & Gray
  • Freshfields Bruckhaus Deringer
  • Kirkland & Ellis

More on Buyouts

Clinical trials and biotechnology
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • Buyouts
  • 04 September 2023
EMEA Public to Private M&A
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • Investments
  • 04 September 2023
HR software solutions providers
Main Capital’s Assessio to be sold to Pollen Street

Recruitment software company tripled in revenue under Main Capital’s ownership

  • Buyouts
  • 25 August 2023
Ice cream
Exponent divests ‘significant' stake in Meadow to Canadian investor

Since 2018, GP has diversified food ingredients company's focus beyond commodity dairy

  • Exits
  • 22 August 2023

Latest News

Fund closes in US dollars
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • 05 September 2023
Clinical trials and biotechnology
  • Buyouts
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • 04 September 2023
Public sector software
  • Exits
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
EMEA Public to Private M&A
  • Investments
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • 04 September 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013